WINT

OQB Windtree Therapeutics, Inc.
Oct 10, 2026 · 5:19 PM ET EOD Market Closed

$0.0010 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.0010, and at the day’s high of $0.0010

YTD change
-96.87%
vs 20-day SMA
+227.87%
vs 200-day SMA
-93.47%

Price ranges

Previous day
$0.0010 $0.0010
open $0.0010 close $0.0010
+$0.0000 (+0.00%)
Today
$0.0010 $0.0010
$0.0010
Past week
$0.0003 $0.0090
from $0.0003 now $0.0010
+$0.0007 (+233.33%)
Past month
$0.0002 $0.0090
from $0.0003 now $0.0010
+$0.0007 (+233.33%)
This year
$0.0001 $0.0349
from $0.0320 now $0.0010
-$0.0310 (-96.87%)

Price & Performance

-0.02 (-94.05%) / 6M

$-0.0019$0.0079$0.0177$0.0275Apr 10Jul 2Oct 8

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 100.0% away from all-time highs of $275,400.0000
  • WINT is down 97% since the beginning of the year
  • WINT is down 99% over the past 12 months
  • WINT is up 233% over the past 1 month
  • 0% of all WINT investors are betting against WINT

WINT reads poor: price sits above one of the two key moving averages, the 12-month move is -99.4%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-1.0848
Earnings momentum N/A Quarterly EPS growth
Quarterly change N/A

Valuation

P/E ratio N/A
Enterprise value $12.8M
Beta 3.66

Balance sheet & scale

IncomeN/A
RevenueN/A
Cash$204.0K
Debt$12.9K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeOQB
Sector Professional, Scientific, and Technical Services
Industry Group Scientific Research and Development Services
Market cap $33.7K

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. It focuses on the treatment of acute cardiovascular and acute pulmonary diseases. It's portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. The company was founded by Evan Myrianthopoulos and James S. Kuo on November 6, 1992 and is headquartered in Warrington, PA.

Competitor comparison

TickerCompany PriceChange
REGN Regeneron Pharmaceuticals, Inc. $746.54 +0.94%
IQV IQVIA Holdings Inc $259.88 +0.39%
CRL Charles River Laboratories International, Inc. $301.79 +1.27%
ICLR ICON Plc $164.17 -0.20%
IT Gartner, Inc. $191.15 -2.18%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.